

### Transform your JCA approach with AI-driven capabilities

The Joint Clinical Assessment (JCA) aims to harmonise clinical evaluations across the EU, reducing duplication of effort for pharmaceutical companies and national HTA bodies. Although it presents new challenges, adopting the right tools can also create opportunities for greater consistency and efficiency in evidence generation across EU markets. Discover how our AI-powered solution can help you succeed in the new era of HTA.

### Challenges JCA Navigator addresses



#### Predicting JCA Requirements:

Use AI to predict PICO scenarios using HTA data.



#### Streamlining Evidence Generation:

Automate data synthesis from diverse sources.



#### Optimising Cross-Market Analysis:

Compare competitor outcomes for strategic planning.



#### Facilitating Collaboration and Communication:

Consolidates data for unified team views.



#### Reducing Resource Strain:

Use AI to automate tasks, freeing resources for strategy.



### JCA Navigator capabilities



#### PICO Overviews:

Specific to indications with longitudinal analyses to identify optimal PICO scenarios for major markets and HTAs.



#### AI-Assisted Data Extraction:

Automated capture of nuanced PICO details from diverse sources, including published literature, HTAs, clinical trials, and guidelines.



#### JCA PICO Simulations:

Helping to inform integrated evidence generation planning for assets entering Phase 3, as well as EU HTA and reimbursement strategies.



#### Comparative Analysis:

Benchmarking outcomes (efficacy, safety, PROs) against competitors to identify relative clinical benefits and data gaps.

### Industry leaders love what we do



Unlock the power of JCA Navigator today.

Contact us to see the full solution in action at [accessinfinity.com/get-in-touch](https://accessinfinity.com/get-in-touch)